IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was SEK 6.87 million compared to SEK 48.96 million a year ago. Revenue was SEK 6.91 million compared to SEK 48.96 million a year ago. Net loss was SEK 142.85 million compared to SEK 80.24 million a year ago. Basic loss per share from continuing operations was SEK 2.75 compared to SEK 1.55 a year ago.